These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 37385905

  • 1. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
    Ni Z, Lu R, Xu X, Bian X, Zhou Z, Yang J, Luo Q, Chen M, Chen C, Sun X, Yu L, He Q, Jiang H, Yuan W, Li Y, Zhou R, Wang J, Zhang X, Zuo L, Meng X, Chang Z, Zhao J, Wessman P, Xiang P, DIALIZE China Study Group.
    Clin Ther; 2023 Jul; 45(7):633-642. PubMed ID: 37385905
    [Abstract] [Full Text] [Related]

  • 2. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [Abstract] [Full Text] [Related]

  • 3. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
    Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.
    BMC Nephrol; 2022 Feb 08; 23(1):59. PubMed ID: 35135481
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N, Nishio T, Osonoi T, Saka Y, Imasawa T, Ohtake T, Mizuno H, Shibagaki Y, Kim H, Yajima T, Sarai N.
    Clin Exp Nephrol; 2020 Dec 08; 24(12):1144-1153. PubMed ID: 32779057
    [Abstract] [Full Text] [Related]

  • 7. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF, Rafique Z, Vishnevskiy K, Michelson E, Vishneva E, Zvereva T, Nahra R, Li D, Miller J.
    Acad Emerg Med; 2020 Jun 08; 27(6):475-486. PubMed ID: 32149451
    [Abstract] [Full Text] [Related]

  • 8. Course of Hyperkalemia in Patients on Hemodialysis.
    Spinowitz B, Fishbane S, Fukagawa M, Ford M, Guzman N, Rastogi A.
    Int J Nephrol; 2022 Jun 08; 2022():6304571. PubMed ID: 35531468
    [Abstract] [Full Text] [Related]

  • 9. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y, Xu R, Wang F, Liu Y, Xu J, Zhao N, Cheng F, Long L, Jia J, Lin S.
    Cardiovasc Drugs Ther; 2021 Oct 08; 35(5):1057-1066. PubMed ID: 33459923
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study.
    Ash SR, Batlle D, Kendrick J, Oluwatosin Y, Pottorf W, Brahmbhatt Y, Guerrieri E, Fried L.
    Nephron; 2022 Oct 08; 146(6):599-609. PubMed ID: 35462371
    [Abstract] [Full Text] [Related]

  • 12. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK, ZS-005 Study Investigators.
    Clin J Am Soc Nephrol; 2019 Jun 07; 14(6):798-809. PubMed ID: 31110051
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD, Lavin PT, Lerma EV, McCullough PA, Butler J, Spinowitz BS, von Haehling S, Kosiborod M, Zhao J, Fishbane S, Packham DK.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):137-150. PubMed ID: 32030422
    [Abstract] [Full Text] [Related]

  • 14. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
    Roger SD, Spinowitz BS, Lerma EV, Fishbane S, Ash SR, Martins JG, Quinn CM, Packham DK.
    Nephrol Dial Transplant; 2021 Apr 26; 36(5):871-883. PubMed ID: 32588050
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.
    Zannad F, Hsu BG, Maeda Y, Shin SK, Vishneva EM, Rensfeldt M, Eklund S, Zhao J.
    ESC Heart Fail; 2020 Feb 26; 7(1):54-64. PubMed ID: 31944628
    [Abstract] [Full Text] [Related]

  • 16. Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients.
    Lewis H, Stamper B, Yungkurth AC.
    Pharmacotherapy; 2024 Jan 26; 44(1):13-21. PubMed ID: 37475499
    [Abstract] [Full Text] [Related]

  • 17. A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit.
    Qu X, Hua Y, Khan BA.
    Cureus; 2023 Sep 26; 15(9):e45058. PubMed ID: 37829953
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis.
    Khandelwal P, Shah S, McAlister L, Cleghorn S, King L, Shroff R.
    Pediatr Nephrol; 2024 Apr 26; 39(4):1213-1219. PubMed ID: 37857905
    [Abstract] [Full Text] [Related]

  • 19. Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults.
    Cheung T, Sun F, Zhao J, Qin Y, Någård M.
    Clin Pharmacol Drug Dev; 2022 Mar 26; 11(3):348-357. PubMed ID: 34997825
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis.
    Fu X, Zhang S, Gao F, Mao N.
    Clin Nephrol; 2024 Oct 26; 102(4):223-231. PubMed ID: 38994592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.